Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
54-week Phase 2 trial of Brazikumab in moderately to severely active ulcerative colitis
2018-001605-93Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brazikumab in autoimmune colitis (3 arms), sponsored by AstraZeneca. Primary endpoint: Clinical remission. Status: unknown.
02
Drugs
brazikumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-001605-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001605-93.